What the FDA labels say about taking them together
Morphine and oxycodone
Morphine's FDA label (Morphine Sulfate) of August 31, 2026 names oxycodone in its drug interactions section, and oxycodone's label names morphine too. The morphine label: “MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity.”
Check it at the source: the morphine FDA label on DailyMed (effective July 13, 2026, Bryant Ranch Prepack); the oxycodone FDA label on DailyMed (effective May 6, 2026, Rhodes Pharmaceuticals LLC).
What does the morphine label say about oxycodone?
Morphine Sulfate label (Fresenius Kabi, USA LLC, August 31, 2026), drug interactionsMonoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (…). Intervention: Do not use Morphine Sulfate Injection in patients taking MAOIs or within 14 days of stopping such treatment. If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, oxymorphone, hydrocodone, or buprenorphine) to treat …
Source: FDA drug label (Morphine Sulfate, NDA204223), Fresenius Kabi, USA LLC, effective August 31, 2026 (SPL set 1f53de80-efc8-4930-b3e3-fba0d026af05), via openFDA
Source: FDA drug label (Morphine sulfate), ANDA078761 (Sun Pharm Inds Ltd), as published by Bryant Ranch Prepack, effective July 13, 2026 (SPL set 595243fe-a4b1-479a-99d6-a084a4181891), via openFDA; the full label on DailyMed
What does the oxycodone label say about morphine?
Oxycodone label, drug interactionsClinical Impact: The concomitant risk of anticholinergic drugs may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. … precipitate withdrawal symptoms. ( 7 ) Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of morphine. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.
Oxycontin label (Knoa Pharma LLC, June 24, 2026), drug interactionsClinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. … precipitate withdrawal symptoms. ( 5.15 , 7 ) Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of morphine. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.
Source: FDA drug label (Roxicodone, NDA021011), SpecGx LLC, effective April 24, 2026 (SPL set 5a8157d3-ba20-4abf-b0d4-6ad141b31d63), via openFDA
Source: FDA drug label (Oxycontin, NDA022272), Knoa Pharma LLC, effective June 24, 2026 (SPL set bfdfe235-d717-4855-a3c8-a13d26dadede), via openFDA
Source: FDA drug label (Oxycodone Hydrochloride), Rhodes Pharmaceuticals LLC, effective May 6, 2026 (SPL set a5162476-1217-41c0-bc7e-0a0f123f069f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Morphine | Oxycodone | |
|---|---|---|
| Labeled for | Pain | Pain |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.226 per tablet 15 mg tablet | $0.0884 per tablet 5 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once